ZIENT

This brand name is authorized in Australia, Ecuador, Mexico, Singapore

Active ingredients

The drug ZIENT contains one active pharmaceutical ingredient (API):

1 Ezetimibe UNII EOR26LQQ24 - EZETIMIBE

Ezetimibe is in a new class of lipid-lowering compounds that selectively inhibit the intestinal absorption of cholesterol. The molecular target of ezetimibe is the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is responsible for the intestinal uptake of cholesterol. Read about Ezetimibe

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ZIENT Tablet	Pharmaceutical Benefits Scheme (AU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C10AX09	Ezetimibe	C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AX Other lipid modifying agents
Discover more medicines within C10AX09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 11408K, 8757X
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 25.068-04-03
Country: MX	Comisión Federal para la Protección contra Riesgos Sanitarios	Identifier(s): 580M2002
Country: SG	Health Sciences Authority	Identifier(s): 14792P